Roche to buy US gene therapy group Spark for $4.3 bn
Swiss pharmaceuticals giant Roche said Monday it reached a deal worth $4.3 billion (3.7 billion euros) to buy US group Spark Therapeutics, which specialises in the development of gene therapy drugs.